Potent EGFR tyrosine kinase inhibitors as anticancer agents

被引：0
|
作者：
Shiao, Hui-Yi [1 ]
Chu, Chang-Ying [1 ]
Hsu, John T. -A. [1 ]
Yeh, Teng-Kuang [1 ]
Hsieh, Hsing-Pang [1 ]
机构：
[1] Natl Hlth Res Inst, Inst Biotechnol & Pharmaceut Res, Zhunan, Miaoli, Taiwan
来源：
ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY | 2011年 / 241卷
关键词：
D O I：
暂无
中图分类号：
O6 [化学];
学科分类号：
0703 ;
摘要：
257-MEDI
引用
收藏
页数：1
相关论文
共 50 条
  • [41] Protein tyrosine kinase inhibitors as therapeutic agents
    Levitzki, A
    BIOORGANIC CHEMISTRY OF BIOLOGICAL SIGNAL TRANSDUCTION, 2001, 211 : 1 - 15
  • [42] Tyrosine Kinase Inhibitors Are Potent Pulmonary Vasodilators in Rats
    Abe, Kohtaro
    Ito, Masako
    Gerthoffer, William T.
    Fagan, Karen A.
    McMurtry, Ivan F.
    Oka, Masahiko
    CIRCULATION, 2009, 120 (18) : S1022 - S1022
  • [43] Colorectal cancer harboring EGFR kinase domain duplication response to EGFR tyrosine kinase inhibitors
    Kondo, Tomohiro
    Kikuchi, Osamu
    Yamamoto, Yoshihiro
    Sunami, Tomohiko
    Wang, Yafeng
    Fukuyama, Keita
    Saito, Tomoki
    Nakahara, Hideto
    Minamiguchi, Sachiko
    Kanai, Masashi
    Sueyoshi, Atsushi
    Muto, Manabu
    ONCOLOGIST, 2024,
  • [44] Characterization of Acquired Receptor Tyrosine Kinase Fusions as Mechanisms of Resistance to EGFR Tyrosine Kinase Inhibitors
    Xu, H.
    Shu, Y.
    Jian, H.
    Shen, J.
    Xiang, J.
    Li, H.
    Li, B.
    Zhang, T.
    Zhang, L.
    Mao, X.
    JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (10) : S562 - S563
  • [45] Drug Tolerance to EGFR Tyrosine Kinase Inhibitors in Lung Cancers with EGFR Mutations
    Suda, Kenichi
    Mitsudomi, Tetsuya
    CELLS, 2021, 10 (07)
  • [46] Disappearance of an activated EGFR mutation after treatment with EGFR tyrosine kinase inhibitors
    Honda, Yoshihiro
    Takigawa, Nagio
    Fushimi, Soichiro
    Ochi, Nobuaki
    Kubo, Toshio
    Ozaki, Saeko
    Tanimoto, Mitsune
    Kiura, Katsuyuki
    LUNG CANCER, 2012, 78 (01) : 121 - 124
  • [47] Potent in vitro activity of Tarloxotinib for EGFR C797S and other mutations refractory to current EGFR tyrosine kinase inhibitors
    Suda, Kenichi
    Nishino, Masaya
    Koga, Takamasa
    Fujino, Toshio
    Kobayashi, Yoshihisa
    Mitsudomi, Tetsuya
    Vellanki, Avanish
    Tirunagaru, Vijaya G.
    CANCER RESEARCH, 2019, 79 (13)
  • [48] QUINAZOLINE INHIBITORS OF THYMIDYLATE SYNTHASE - POTENT NEW ANTICANCER AGENTS
    MARSHAM, PR
    JOURNAL OF HETEROCYCLIC CHEMISTRY, 1994, 31 (03) : 603 - 613
  • [49] Design and synthesis of Aurora kinase inhibitors as anticancer agents
    Hsu, Yung Chang
    Shiao, Hui-Yi
    Lin, Wen-Hsing
    Hsu, John Tsu-An
    Chen, Chiung-Tong
    Chao, Yu-Sheng
    Hsieh, Hsing-Pang
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2013, 245
  • [50] Strategies for overcoming resistance to EGFR family tyrosine kinase inhibitors
    Giaccone, Giuseppe
    Wang, Yisong
    CANCER TREATMENT REVIEWS, 2011, 37 (06) : 456 - 464
12345